Afuco™ Anti-TFPI ADCC Therapeutic Antibody (Concizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human TFPI. Concizumab is a monoclonal IgG4 antibody (mAb) that binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI thereby blocking the interaction of this domain with the active site of FXa.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-734 |
| Pricing | Inquiry |
| Host | Human |
| Target | TFPI |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |